AR057063A1 - Moduladores de tienopirimidina y tienopiridina quinasa y composicion farmaceutica - Google Patents
Moduladores de tienopirimidina y tienopiridina quinasa y composicion farmaceuticaInfo
- Publication number
- AR057063A1 AR057063A1 ARP060102425A ARP060102425A AR057063A1 AR 057063 A1 AR057063 A1 AR 057063A1 AR P060102425 A ARP060102425 A AR P060102425A AR P060102425 A ARP060102425 A AR P060102425A AR 057063 A1 AR057063 A1 AR 057063A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- heteroaryl
- alkylamino
- cycloalkyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 14
- -1 oxazolidinonyl Chemical group 0.000 abstract 8
- 125000001072 heteroaryl group Chemical group 0.000 abstract 6
- 125000003282 alkyl amino group Chemical group 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000004475 heteroaralkyl group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical group O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 abstract 1
- DBDCNCCRPKTRSD-UHFFFAOYSA-N thieno[3,2-b]pyridine Chemical class C1=CC=C2SC=CC2=N1 DBDCNCCRPKTRSD-UHFFFAOYSA-N 0.000 abstract 1
- 125000004001 thioalkyl group Chemical group 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Materials For Medical Uses (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente está dirigida un compuestos tienopirimidinas y tienopiridinas de formula (1) y formula (2). La presente está además dirigida un las composiciones farmacéuticas que comprenden los compuestos de la presente y un los métodos para tratar trastornos tales como cánceres y otros desordenes proliferativos de células. Reivindicacion 1: Un compuesto seleccionado del grupo que consiste en la formula (1) y en la formula (2), y N-oxidos, sales farmacéuticamente aceptables, y isomeros estereoquímicos de estos, donde: q es 0, 1 o 2; p es 0 o 1; Q es NH, N(alquilo), O, o un enlace directo; X es N o CH; Z es NH, N(alquilo), o CH2; B es arilo, cicloalquilo, heteroarilo, o un heteroarilo benzo-fusionado de nueve un diez miembros; R1 es un grupo de formulas (3) un (7), donde n es 1, 2, 3 o 4; Ra es hidrogeno, heteroarilo opcionalmente sustituido con R5, hidroxilo, alquilamino, dialquilamino, oxazolidinonilo opcionalmente sustituido con R5, pirrolidinonilo opcionalmente sustituido con R5, piperidinonilo opcionalmente sustituido con R5, heterodionilo cíclico opcionalmente sustituido con R5, heterociclilo opcionalmente sustituido con R5, -COORy,, -CONRwRx, -N(Ry)CON(Rw)(Rx), -N(Rw)C(O)ORx, -N(Rw)CORy, -SRy, -SORy, - SO2Ry, -NRwSO2Ry, -NRwSO2Rx, -SO3Ry, o -OSO2NRWRX; Rbb es hidrogeno, halogeno, arilo, heteroarilo, o heterociclilo; R5 es uno, dos, o tres sustituyentes independientemente seleccionados de: halogeno, ciano, trifluormetilo, amino, hidroxilo, alcoxi, - C(O)alquilo, -SO2alquilo, -C(O)N(alquilo)2, alquilo, -alquiloC1-4-OH, o alquilamino; Rw y Rx están independientemente seleccionados de: hidrogeno, alquilo, alquenilo, aralquilo, o heteroaralquilo, o Rw y Rx pueden tomarse conjuntamente, opcionalmente para formar un anillo 5 un 7 miembros, que contiene opcionalmente una heteroporcion seleccionada de O, NH, N(alquilo), SO2, SO, o S; Ry está seleccionado de: hidrogeno, alquilo, alquenilo, cicloalquilo, arilo, aralquilo, heteroaralquilo, o heteroarilo; y R3 es uno o más sustituyentes, que están opcionalmente presentes, y que están independientemente seleccionados de: alquilo, alcoxi, halogeno, alcoxiéter, hidroxilo, tio, nitro, cicloalquilo opcionalmente sustituido con R4, heteroarilo opcionalmente sustituido con R4, alquilamino, heterociclilo opcionalmente sustituido con R4, heterociclilo parcialmente insaturado que está opcionalmente sustituido con R4, -O(cicloalquilo), pirrolidinona opcionalmente sustituido con R4, fenoxi opcionalmente sustituido con R4, -CN, -OCHF2, -OCF3, -CF3, alquilo halogenado, heteroariloxi opcionalmente sustituido con R4, dialquilamino, -NHSO2alquilo, tioalquilo, o -SO2alquilo; donde R4 está independientemente seleccionado de: halogeno, ciano, trifluorometilo, amino, hidroxilo, alcoxi, -C(O)alquilo, -CO2alquilo, -SO2alquilo, -C(O)N(alquilo)2, alquilo, o alquilamino.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68971005P | 2005-06-10 | 2005-06-10 | |
| US74694106P | 2006-05-10 | 2006-05-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR057063A1 true AR057063A1 (es) | 2007-11-14 |
Family
ID=37074647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060102425A AR057063A1 (es) | 2005-06-10 | 2006-06-09 | Moduladores de tienopirimidina y tienopiridina quinasa y composicion farmaceutica |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20060281768A1 (es) |
| EP (1) | EP1899355A1 (es) |
| JP (1) | JP2008543759A (es) |
| KR (1) | KR20080021126A (es) |
| AR (1) | AR057063A1 (es) |
| AU (1) | AU2006258049A1 (es) |
| BR (1) | BRPI0613644A2 (es) |
| CA (1) | CA2611587A1 (es) |
| CR (1) | CR9650A (es) |
| EA (1) | EA200800011A1 (es) |
| EC (1) | ECSP077992A (es) |
| IL (1) | IL187689A0 (es) |
| MX (1) | MX2007015741A (es) |
| NI (1) | NI200700311A (es) |
| NO (1) | NO20080162L (es) |
| PE (1) | PE20070070A1 (es) |
| TW (1) | TW200716651A (es) |
| UY (1) | UY29590A1 (es) |
| WO (1) | WO2006135639A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| US20090124610A1 (en) * | 2006-04-25 | 2009-05-14 | Gordon Saxty | Pharmaceutical compounds |
| DK3421471T3 (da) | 2006-04-25 | 2021-06-14 | Astex Therapeutics Ltd | Purin- og deazapurinderivater som farmaceutiske forbindelser |
| EP2066642A1 (en) * | 2006-09-25 | 2009-06-10 | Arete Therapeutics, INC. | Soluble epoxide hydrolase inhibitors |
| NZ583509A (en) | 2007-09-14 | 2012-01-12 | Janssen Pharmaceutica Nv | Thieno-and furo-pyrimidine modulators of the histamine h4 receptor |
| MX2010003927A (es) | 2007-10-11 | 2010-04-30 | Astrazeneca Ab | Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas cinasas b. |
| MX357447B (es) | 2011-04-01 | 2018-07-10 | Astrazeneca Ab | Tratamiento terapeutico. |
| SMT201700035T1 (it) | 2011-05-13 | 2017-03-08 | Array Biopharma Inc | Composti di pirrolidinil urea, pirrolidinil tiourea e pirrolidinil guanidina come inibitori di chinasi trka |
| AR090037A1 (es) * | 2011-11-15 | 2014-10-15 | Xention Ltd | Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio |
| ES2762250T5 (es) | 2011-11-30 | 2023-01-05 | Astrazeneca Ab | Tratamiento combinado del cáncer |
| AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
| HRP20191593T1 (hr) | 2014-05-15 | 2019-11-29 | Array Biopharma Inc | 1-((3s,4r)-4-(3-fluorfenil)-1-(2-metoksietil)pirolidin-3-il)-3-(4-metil-3-(2-metilpirimidin-5-il)-1-fenil-1h-pirazol-5-il)urea kao inhibitor trka kinaze |
| WO2018118598A1 (en) * | 2016-12-23 | 2018-06-28 | Arvinas, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| KR101954370B1 (ko) | 2018-07-25 | 2019-03-05 | 한미약품 주식회사 | 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
| US11168093B2 (en) | 2018-12-21 | 2021-11-09 | Celgene Corporation | Thienopyridine inhibitors of RIPK2 |
| BR112021016522A2 (pt) | 2019-02-22 | 2021-10-26 | Hanmi Pharm. Co., Ltd. | Composição farmacêutica para o tratamento da leucemia mieloide aguda |
| MX2021015724A (es) | 2019-06-27 | 2022-05-16 | Hanmi Pharm Ind Co Ltd | Composición farmacéutica para el tratamiento de la leucemia mieloide aguda, que contiene inhibidores de flt3 y agentes quimioterapéuticos. |
| WO2024248513A1 (en) * | 2023-05-31 | 2024-12-05 | Hanmi Pharm. Co., Ltd. | Solid dispersion of myeloid kinome inhibitors and pharmaceutical composition comprising the same |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2193143T3 (es) * | 1992-03-05 | 2003-11-01 | Univ Texas | Uso de inmunoconjugados para la diagnosis y/o terapia de tumores vascularizaos. |
| US5474765A (en) * | 1992-03-23 | 1995-12-12 | Ut Sw Medical Ctr At Dallas | Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells |
| US5932765A (en) * | 1997-05-23 | 1999-08-03 | Merck Patent Gesellschaft Mit | Nitromethyl ketones, process for preparing them and compositions containing them |
| KR100446363B1 (ko) * | 1997-11-11 | 2004-09-01 | 화이자 프로덕츠 인코포레이티드 | 항암제로 유용한 티에노피리미딘 및 티에노피리딘 유도체 |
| AU745425B2 (en) * | 1998-01-27 | 2002-03-21 | Aventis Pharmaceuticals Inc. | Substituted oxoazaheterocyclyl factor Xa inhibitors |
| IL145941A (en) * | 1999-04-28 | 2007-08-19 | Univ Texas | Compositions and methods for cancer treatment by selectively inhibiting vegf |
| US6776796B2 (en) * | 2000-05-12 | 2004-08-17 | Cordis Corportation | Antiinflammatory drug and delivery device |
| DE10110750A1 (de) * | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| AR035885A1 (es) * | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
| US7105505B2 (en) * | 2002-04-18 | 2006-09-12 | Schering Corporation | Benzimidazole derivatives useful as histamine H3 antagonists |
| MY141867A (en) * | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| HK1080067A1 (en) * | 2002-08-12 | 2006-04-21 | Takeda Pharmaceutical Company Limited | Fused benzene derivative and use |
| AU2003280599A1 (en) * | 2002-10-29 | 2004-05-25 | Kirin Beer Kabushiki Kaisha | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME |
| US20050026944A1 (en) * | 2003-07-24 | 2005-02-03 | Patrick Betschmann | Thienopyridine and furopyridine kinase inhibitors |
| US20060281769A1 (en) * | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators |
-
2006
- 2006-06-06 US US11/422,359 patent/US20060281768A1/en not_active Abandoned
- 2006-06-07 MX MX2007015741A patent/MX2007015741A/es unknown
- 2006-06-07 NI NI200700311A patent/NI200700311A/es unknown
- 2006-06-07 AU AU2006258049A patent/AU2006258049A1/en not_active Abandoned
- 2006-06-07 EA EA200800011A patent/EA200800011A1/ru unknown
- 2006-06-07 WO PCT/US2006/022151 patent/WO2006135639A1/en not_active Ceased
- 2006-06-07 EP EP06772445A patent/EP1899355A1/en not_active Withdrawn
- 2006-06-07 JP JP2008515879A patent/JP2008543759A/ja not_active Withdrawn
- 2006-06-07 BR BRPI0613644-3A patent/BRPI0613644A2/pt not_active Application Discontinuation
- 2006-06-07 CA CA002611587A patent/CA2611587A1/en not_active Abandoned
- 2006-06-07 KR KR1020087000618A patent/KR20080021126A/ko not_active Withdrawn
- 2006-06-08 UY UY29590A patent/UY29590A1/es unknown
- 2006-06-08 PE PE2006000640A patent/PE20070070A1/es not_active Application Discontinuation
- 2006-06-09 AR ARP060102425A patent/AR057063A1/es not_active Application Discontinuation
- 2006-06-09 TW TW095120482A patent/TW200716651A/zh unknown
-
2007
- 2007-11-27 IL IL187689A patent/IL187689A0/en unknown
- 2007-12-10 EC EC2007007992A patent/ECSP077992A/es unknown
-
2008
- 2008-01-09 NO NO20080162A patent/NO20080162L/no not_active Application Discontinuation
- 2008-01-09 CR CR9650A patent/CR9650A/es not_active Application Discontinuation
-
2009
- 2009-01-30 US US12/362,933 patent/US20090143378A1/en not_active Abandoned
- 2009-01-30 US US12/363,043 patent/US20090163710A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0613644A2 (pt) | 2011-01-25 |
| US20060281768A1 (en) | 2006-12-14 |
| NO20080162L (no) | 2008-03-07 |
| EP1899355A1 (en) | 2008-03-19 |
| TW200716651A (en) | 2007-05-01 |
| PE20070070A1 (es) | 2007-03-08 |
| UY29590A1 (es) | 2006-10-02 |
| AU2006258049A1 (en) | 2006-12-21 |
| NI200700311A (es) | 2009-03-03 |
| KR20080021126A (ko) | 2008-03-06 |
| AU2006258049A8 (en) | 2006-12-21 |
| CR9650A (es) | 2008-09-09 |
| WO2006135639A1 (en) | 2006-12-21 |
| MX2007015741A (es) | 2008-04-29 |
| CA2611587A1 (en) | 2006-12-21 |
| JP2008543759A (ja) | 2008-12-04 |
| US20090163710A1 (en) | 2009-06-25 |
| IL187689A0 (en) | 2008-08-07 |
| US20090143378A1 (en) | 2009-06-04 |
| EA200800011A1 (ru) | 2008-06-30 |
| ECSP077992A (es) | 2008-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR057063A1 (es) | Moduladores de tienopirimidina y tienopiridina quinasa y composicion farmaceutica | |
| RU2500680C2 (ru) | Новые замещенные пиридин-2-оны и пиридазин-3-оны | |
| AR057062A1 (es) | Moduladores de aminoquinolina y aminoquinazolina quinasa | |
| PE20181449A1 (es) | Compuestos utiles como inhibidores de cinasa | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| PE20190336A1 (es) | Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| PE20151951A1 (es) | Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b | |
| AR074021A1 (es) | Compuestos heterociclicos fusionados como moduladores del canal ionico | |
| AR023152A1 (es) | Compuesto tienopirimidina, procedimiento para producirlo, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar dichacomposicion | |
| PE20142081A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos | |
| AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
| AR080596A1 (es) | Compuestos alquilamido y composiciones farmaceuticas | |
| AR089774A1 (es) | Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
| HUP0401784A2 (hu) | Heterobiciklikus szerkezetû virális polimeráz inhibitorok, eljárás az elõállításukra, köztitermékek és ezeket tartalmazó gyógyszerkészítmények | |
| WO2007016392A3 (en) | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors | |
| PE20170946A1 (es) | 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
| AR078756A1 (es) | Moduladores alostericos positivos (map) | |
| AR086100A1 (es) | Compuestos de cromenona y composiciones farmaceuticas que los contienen | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| IL183373A0 (en) | 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof | |
| AR065249A1 (es) | Derivados nitrogenados condensados de analogos de nucleosidos, composiciones farmaceuticas que los contienen y usos para tratar y/o prevenir infecciones virales. | |
| AR053895A1 (es) | Aminopirimidinas como moduladores de quinasas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |